Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384364 | 0.79 | PDE3B (0.47) | PDE3BPDE3APDE2AALDH1A1MAPT | |
| SCHEMBL7140402 | 0.79 | PRMT5 (0.44) | GAAKMT2APRMT5WDR77FGFR1 | |
| SCHEMBL5844145 | 0.78 | PDE3B (0.40) | PDE3BPDE3APDE2AALDH1A1MAPT | |
| SCHEMBL29569459 | 0.71 | MAPT (0.46) | PDE3BPDE3APDE2AALDH1A1MAPT | |
| SCHEMBL9686737 | 0.71 | GAA (0.63) | PDE3BPDE3APDE2AALDH1A1MAPT | |
| Acetamide SCHEMBL5843146 | 0.70 | IKBKB (0.37) | PDE3BPDE3APDE2AALDH1A1MAPT | |
| SCHEMBL7447282 | 0.69 | FKBP5 (0.53) | PDE3BPDE3APDE2AALDH1A1MAPT | |
| SCHEMBL7421917 | 0.68 | HPGD (0.38) | PDE3BPDE3APDE2AALDH1A1MAPT | |
| SCHEMBL7547477 | 0.67 | KDM4E (0.44) | PDE3BPDE3APDE2AALDH1A1MAPT | |
| SCHEMBL11389056 | 0.64 | KDM4E (0.44) | PDE3BPDE3APDE2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006252-A1 | DUAL INHIBITION OF MDM2 AND EIF2-ALPHA INDUCES CELL DEATH IN MULTIPLE CANCER CELL TYPES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-01-04 | — | — | WO | claimed |
| US-20220202950-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2022-06-30 | — | — | US | claimed |
| WO-2020222161-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2020-11-05 | — | — | WO | claimed |
| US-10822374-B2 | Cancer therapies and diagnostics | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-03 | — | — | US | claimed |
| US-20180008688-A1 | METHOD AND COMPOSITIONS FOR ENHANCING IMMUNOTHERAPEUTIC TREATMENT OF A CANCER | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. | 2018-01-11 | — | — | US | claimed |
| US-20170348266-A1 | INHIBITION OF PROLINE CATABOLISM FOR THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS | BUCK INSTITUTE FOR RESEARCH ON AGING | 2017-12-07 | — | — | US | claimed |
| WO-2016077632-A2 | INHIBITION OF PROLINE CATABOLISM FOR THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2016-05-19 | — | — | WO | claimed |
| US-20130331398-A1 | MODULATION OF UBIQUITINATION OF SYNAPTIC PROTEINS FOR THE TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISORDERS | UNIVERSITY OF MASSACHUSETTS (US) | 2013-12-12 | — | — | US | claimed |
| WO-2012065182-A2 | MODULATION OF UBIQUITINATION OF SYNAPTIC PROTEINS FOR THE TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISORDERS | UNIVERSITY OF MASSACHUSETTS (US) | 2012-05-18 | — | — | WO | claimed |
| US-7090828-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-08-15 | — | — | US | claimed |
| US-6569402-B1 | Targeting moiety that binds to receptor upregulated during angiogenesis, and a radioisotope or diagnostically imageable moiety; receptor integrin and compound is a benzodiazepine, benzodiazepinedione, or dibenzotrihydroannulene nonapeptide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-27 | — | — | US | claimed |
| EP-1311292-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Bristol-Myers Squibb Pharma Company (US) | 2003-05-21 | — | — | EP | claimed |
| US-20020019013-A1 | Combined resin method for high-speed synthesis of combinatorial libraries | ADVANCED SYNTECH, LLC | 2002-02-14 | — | — | US | claimed |
| WO-2001097861-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| EP-1140864-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2001030769-A2 | PROCESS FOR ALKYLATION OF BENZODIAZEPINDIONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2001-05-03 | — | — | WO | claimed |
| WO-2000035887-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARM CO (US) | 2000-06-22 | — | — | WO | claimed |
| EP-0610334-B1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII B III A RECEPTOR | GENENTECH INC (US) | 1996-01-24 | — | — | EP | claimed |
| EP-0610334-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII b?III a? RECEPTOR. | GENENTECH INC (US) | 1994-08-17 | — | — | EP | claimed |
| WO-1993008174-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPIIbIIIa RECEPTOR | GENENTECH, INC. (US) | 1993-04-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348266-A1 | INHIBITION OF PROLINE CATABOLISM FOR THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS | GLUL, GLS2, PHGDH | PDE3B 3247/4885PDE3A 3276/4885PDE2A 3116/4885 |
| US-10822374-B2 | Cancer therapies and diagnostics | TP53, TP53BP1, MYC | PDE3B 4494/4885PDE3A 4527/4885PDE2A 4463/4885 |
| US-20020019013-A1 | Combined resin method for high-speed synthesis of combinatorial libraries | CPSF1, CPSF6, PLAU | PDE3B 2379/4885PDE3A 2150/4885PDE2A 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.